XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Financial Statement Components
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Financial Statement Components

7. Financial Statement Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

 

 

As of

 

(In thousands)

 

June 30,
2022

 

 

December 31,
2021

 

Prepaid clinical trial services

 

$

1,207

 

 

$

2,038

 

Prepaid research and development expenses

 

 

1,438

 

 

 

2,074

 

Prepaid insurance

 

 

1,935

 

 

 

4,701

 

Other prepaid expenses

 

 

2,271

 

 

 

2,225

 

Interest receivable

 

 

981

 

 

 

729

 

Other

 

 

1,101

 

 

 

562

 

Prepaid expenses and other current assets

 

$

8,933

 

 

$

12,329

 

 

Property and Equipment, Net

Property and equipment, net consisted of the following:

 

 

As of

 

(In thousands)

 

June 30,
2022

 

 

December 31,
2021

 

Computer equipment and software

 

$

996

 

 

$

946

 

Furniture and fixtures

 

 

459

 

 

 

437

 

Laboratory equipment

 

 

9,001

 

 

 

5,617

 

Leasehold improvements

 

 

23,466

 

 

 

23,286

 

Construction in progress

 

 

199

 

 

 

729

 

Less: Accumulated depreciation

 

 

(4,807

)

 

 

(2,566

)

Property and equipment, net

 

$

29,314

 

 

$

28,449

 

Other Long-Term Assets

Other long-term assets consisted of the following:

 

 

As of

 

(In thousands)

 

June 30,
2022

 

 

December 31,
2021

 

Other prepaid expenses, net of current portion

 

$

1,737

 

 

$

1,806

 

Deferred expenses associated with financing activities

 

 

465

 

 

 

485

 

Other

 

 

560

 

 

 

442

 

Other long-term assets

 

$

2,762

 

 

$

2,733

 

As of June 30, 2022 and December 31, 2021, other prepaid expenses, net of current portion, primarily consisted of deposits paid under certain contract research organization agreements that will be held until the completion of the related clinical trials that are anticipated to end more than 12 months from the balance sheet date.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

 

 

As of

 

(In thousands)

 

June 30,
2022

 

 

December 31,
2021

 

Accrued external research and development services

 

$

30,659

 

 

$

16,097

 

Accrued compensation and personnel costs

 

 

8,272

 

 

 

10,827

 

Accrued property and equipment

 

 

311

 

 

 

109

 

Accrued professional fees and consulting services

 

 

2,931

 

 

 

1,270

 

Other

 

 

890

 

 

 

500

 

Accrued expenses and other current liabilities

 

$

43,063

 

 

$

28,803

 

Other Income (Expense), net

Other income (expense), net consisted of the following:

 

 

For the Three Months Ended
June 30,

 

 

For the Six Months Ended
June 30,

 

(In thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Gain (loss) on fair value remeasurement of financing liability, related party

 

$

930

 

 

$

(496

)

 

$

2,900

 

 

$

(496

)

Gain (loss) on fair value remeasurement of financing liability

 

 

930

 

 

 

(496

)

 

 

2,900

 

 

 

(496

)

Loss on fair value remeasurement of private placement warrants

 

 

 

 

 

(1,746

)

 

 

 

 

 

(2,170

)

Other, net

 

 

8

 

 

 

(1

)

 

 

9

 

 

 

(2

)

Other income (expense), net

 

$

1,868

 

 

$

(2,739

)

 

$

5,809

 

 

$

(3,164

)